Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
CRISPR offers new hope for many patients and promises to transform the way we think of future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical translation and specific recommendations have been recently released by the FDA. Rapid progress in the preclinical and clinic...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1138596/full |
| _version_ | 1828014361883443200 |
|---|---|
| author | Radwa Ewaisha Radwa Ewaisha Karen S. Anderson |
| author_facet | Radwa Ewaisha Radwa Ewaisha Karen S. Anderson |
| author_sort | Radwa Ewaisha |
| collection | DOAJ |
| description | CRISPR offers new hope for many patients and promises to transform the way we think of future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical translation and specific recommendations have been recently released by the FDA. Rapid progress in the preclinical and clinical development of CRISPR therapeutics leverages years of experience with gene therapy successes and failures. Adverse events due to immunogenicity have been a major setback that has impacted the field of gene therapy. As several in vivo CRISPR clinical trials make progress, the challenge of immunogenicity remains a significant roadblock to the clinical availability and utility of CRISPR therapeutics. In this review, we examine what is currently known about the immunogenicity of CRISPR therapeutics and discuss several considerations to mitigate immunogenicity for the design of safe and clinically translatable CRISPR therapeutics. |
| first_indexed | 2024-04-10T10:00:59Z |
| format | Article |
| id | doaj.art-3c47b5197cda478496567a64a50b5d48 |
| institution | Directory Open Access Journal |
| issn | 2296-4185 |
| language | English |
| last_indexed | 2024-04-10T10:00:59Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj.art-3c47b5197cda478496567a64a50b5d482023-02-16T08:04:41ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852023-02-011110.3389/fbioe.2023.11385961138596Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translationRadwa Ewaisha0Radwa Ewaisha1Karen S. Anderson2Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, EgyptDepartment of Microbiology and Immunology, School of Pharmacy, Newgiza University, Newgiza, EgyptCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, United StatesCRISPR offers new hope for many patients and promises to transform the way we think of future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical translation and specific recommendations have been recently released by the FDA. Rapid progress in the preclinical and clinical development of CRISPR therapeutics leverages years of experience with gene therapy successes and failures. Adverse events due to immunogenicity have been a major setback that has impacted the field of gene therapy. As several in vivo CRISPR clinical trials make progress, the challenge of immunogenicity remains a significant roadblock to the clinical availability and utility of CRISPR therapeutics. In this review, we examine what is currently known about the immunogenicity of CRISPR therapeutics and discuss several considerations to mitigate immunogenicity for the design of safe and clinically translatable CRISPR therapeutics.https://www.frontiersin.org/articles/10.3389/fbioe.2023.1138596/fullCRISPR-Casimmunogenicityclinical translationCas9genome editinggene therapy |
| spellingShingle | Radwa Ewaisha Radwa Ewaisha Karen S. Anderson Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation Frontiers in Bioengineering and Biotechnology CRISPR-Cas immunogenicity clinical translation Cas9 genome editing gene therapy |
| title | Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation |
| title_full | Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation |
| title_fullStr | Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation |
| title_full_unstemmed | Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation |
| title_short | Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation |
| title_sort | immunogenicity of crispr therapeutics critical considerations for clinical translation |
| topic | CRISPR-Cas immunogenicity clinical translation Cas9 genome editing gene therapy |
| url | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1138596/full |
| work_keys_str_mv | AT radwaewaisha immunogenicityofcrisprtherapeuticscriticalconsiderationsforclinicaltranslation AT radwaewaisha immunogenicityofcrisprtherapeuticscriticalconsiderationsforclinicaltranslation AT karensanderson immunogenicityofcrisprtherapeuticscriticalconsiderationsforclinicaltranslation |